Clinical trials
Phase 2/3 Attention Deficit Disorder with Hyperactivity trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
14 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 1 |
| 2005 | 1 |
| 2007 | 1 |
| 2009 | 2 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 2 |
| 2021 | 1 |
| 2023 | 1 |
| 2024 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 12 |
| Terminated | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| New York State Psychiatric Institute | 3 |
| Eli Lilly and Company | 2 |
| Massachusetts General Hospital | 2 |
| Neurocentria, Inc. | 2 |
| Aevi Genomic Medicine, LLC, a Cerecor company | 1 |
| Alcobra Ltd. | 1 |
| Sumitomo Pharma America, Inc. | 1 |
| The University of Texas Health Science Center, Houston | 1 |
| University of Utah | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Attention Deficit Disorder with Hyperactivity | 14 |
| Cocaine-Related Disorders | 2 |
| Autistic Disorder | 1 |
| Opioid-Related Disorders | 1 |
Trials
Showing 1 to 14 of 14. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.